Allarity CEO to present company overview at Pharma Partnering Summit US on May 14-15

Allarity Therapeutics, Inc.

CEO Thomas H. Jensen will deliver a company overview on stenoparib (dual PARP/WNT inhibitor) and DRP® platform.
One-on-one meetings will be conducted at the event in San Diego, CA on May 14-15, 2025.
Participation is a standard business development and licensing conference activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.